Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February

  Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth
  Quarter and Year 2012 Financial Results on February 12, 2013

Business Wire

BOTHELL, Wash. -- January 29, 2013

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its
fourth quarter and year 2012 financial results on Tuesday, February 12, 2013,
after the close of financial markets. Following the announcement, company
management will host a conference call and webcast discussion of the results
and provide a general corporate update. Access to the event can be obtained as
follows:

LIVE access on Tuesday, February 12, 2013

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

  *Telephone 877-941-6009 (domestic) or 480-629-9818 (international);
    conference ID 4594357
  *Webcast available at http://www.seattlegenetics.com/ in the Investors and
    News section

REPLAY access

  *Telephone replay will be available beginning at approximately 3:30 p.m. PT
    on Tuesday, February 12, 2013, through 5:00 p.m. PT on Friday, February
    15, 2013, by calling 800-406-7325 (domestic) or 303-590-3030
    (international); conference ID 4594357
  *Webcast replay will be available on the Seattle Genetics website at
    http://www.seattlegenetics.com/ in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and
commercialization of monoclonal antibody-based therapies for the treatment of
cancer. The company’s lead program, ADCETRIS, received accelerated approval
from the U.S. Food and Drug Administration in August 2011 for two indications.
In addition, under a collaboration with Millennium: The Takeda Oncology
Company, ADCETRIS received conditional approval from the European Commission
in October 2012. Seattle Genetics also has three other clinical-stage
antibody-drug conjugate (ADC) programs: SGN-75, ASG-5ME and ASG-22ME. Seattle
Genetics has collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including Abbott, Agensys (an
affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo,
Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC
co-development agreements with Agensys and Genmab. More information can be
found at www.seattlegenetics.com.

Contact:

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
 
Press spacebar to pause and continue. Press esc to stop.